CSIMarket
 
Cryoport inc   (CYRX)
Other Ticker:  
 
 
Price: $16.1300 $-0.34 -2.064%
Day's High: $16.73 Week Perf: -5.23 %
Day's Low: $ 15.59 30 Day Perf: 7.39 %
Volume (M): 515 52 Wk High: $ 24.17
Volume (M$): $ 8,301 52 Wk Avg: $15.80
Open: $16.39 52 Wk Low: $9.00



 Market Capitalization (Millions $) 785
 Shares Outstanding (Millions) 49
 Employees 31
 Revenues (TTM) (Millions $) 233
 Net Income (TTM) (Millions $) -108
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) 45

Cryoport Inc

We provide cryogenic logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology and specialized cold chain logistics knowhow. We view our solutions as disruptive to the “older technologies” of dry ice and liquid nitrogen, in that our solutions are comprehensive and combine our competencies in configurations that are customized to our client’s requirements. We provide comprehensive, reliable, economic alternatives to all existing logistics solutions and services utilized for frozen shipping in the life sciences industry (e.g., personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to cryogenic or frozen temperatures). As part of our services we provide the ability to monitor, record and archive crucial information for each shipment that can be used for scientific and regulatory purposes.

Our Cryoport Express® Solutions include a sophisticated cloud-based logistics operating platform, which is branded as the Cryoportal™. The Cryoportal™ supports the management of the entire shipment and logistics process through a single interface, including initial order input, document preparation, customs clearance, courier management, shipment tracking, issue resolution, and delivery. In addition, it provides unique and incisive information dashboards and validation documentation for every shipment. The Cryoportal™ records and retains a fully documented “chain-of-custody” and, at the client’s option, “chain-of-condition” for every shipment, helping ensure that quality, safety, efficacy, and stability of shipped commodities are maintained throughout the process. This recorded and archived information allows our clients to meet exacting requirements necessary for scientific work and for proof of regulatory compliance during the logistics phase.

The branded packaging for our Cryoport Express® Solutions includes our liquid nitrogen dry vapor shippers, the Cryoport Express® Shippers. The Cryoport Express® Shippers are cost-effective and reusable cryogenic transport containers (our standard shipper is a patented vacuum flask) utilizing an innovative application of “dry vapor” liquid nitrogen (“LN2”) technology. Cryoport Express® Shippers are International Air Transport Association (“IATA”) certified and validated to maintain stable temperatures of minus 150° C and below for a 10-day dynamic shipment period. The Company currently features three Cryoport Express® Shippers: the Standard Dry Shipper (holding up to 75 2.0 ml vials), the High Volume Dry Shipper (holding up to 500 2.0 ml vials) and the recently introduced Cryoport Express® CXVC1 Shipper (holding up to 1,500 2.0 ml vials). In addition, we assist clients with internal secondary packaging (e.g., vials, canes, straws and plates).

Our most used solution is the “turnkey” solution, which can be accessed directly through our cloud-based Cryoportal™ or by contacting Cryoport Client Care for order entry. Once an order is placed and cleared, we ship a fully charged Cryoport Express® Shipper to the client who conveniently loads its frozen commodity into the inner chamber of the Cryoport Express® Shipper. The customer then closes the shipper package and reseals the shipping box displaying the next recipient’s address (“Flap A”) for pre-arranged carrier pick up. Cryoport arranges for the pick-up of the parcel by a shipping service provider, which is designated by the client or chosen by Cryoport, for delivery to the client’s intended recipient. The recipient simply opens the shipper package and removes the frozen commodity that has been shipped. The recipient then reseals the package, displaying the nearest Cryoport Staging Center address, making it ready for pre-arranged carrier pick-up. When the Cryoport Staging Center receives the Cryoport Express® Shipper, it is cleaned, put through quality assurance testing, and returned to inventory for reuse.


“Customer Staged Solution,” designed for clients making 50 or more shipments per month. Under this solution, we supply an inventory of our Cryoport Express® Shippers to our customer, in an uncharged state, enabling our customer (after training/certification) to charge them with liquid nitrogen and use our Cryoportal™ to enter orders with shipping and delivery service providers for the transportation of the package.

“Customer Managed Solution,” a limited customer implemented solution, whereby we supply our Cryoport Express® Shippers to clients in a fully charged state, but leaving it to the client to manage the shipping, including the selection of the shipping and delivery service provider and the return of the shipper to us.

“powered by CryoportSM,” available to providers of shipping and delivery services who seek to offer a “branded” cryogenic logistics solution as part of their service offerings, with “powered by CryoportSM” appearing prominently on the offering software interface and packaging. This solution can also be private labeled upon meeting certain requirements, such as minimum required shipping volumes.

“Integrated Solution,” which is our total outsource solution. It is our most comprehensive solution and involves our management of the entire cryogenic logistics process for our client, including Cryoport employees at the client’s site to manage the client’s cryogenic logistics function in total.

“Regenerative Medicine Point-of-Care Repository Solution,” designed for allogeneic therapies. In this solution we supply our Cryoport Express® Shipper to ship and store cryogenically preserved life science products for up to six days (or longer periods with supplementary shippers) at a point-of-care site, with the Cryoport Express® Shipper serving as a temporary freezer/repository enabling the efficient and effective distribution of temperature sensitive allogeneic cell-based therapies without the expense, inconvenience, and potential costly failure of an on-sight, cryopreservation device.

“Personalized Medicine and Cell-based Immunotherapy Solution,” designed for autologous therapies. In this solution our Cryoport Express® Shipper serves as an enabling technology for the safe transportation of manufactured autologous cellular-based immunotherapy market by providing a comprehensive logistics solution for the verified chain of custody and condition transport from, (a) the collection of the patient’s cells in a hospital setting, to (b) a central processing facility where they are manufactured into a personalized medicine, to (c) the safe, cryogenically preserved return of these irreplaceable cells to a point-of-care treatment facility. If required, the Cryoport Express® Shipper can then serve as a temporary freezer/repository to allow the efficient distribution of this personalized medicine to the patient when and where the medical provider needs it most without the expense, inconvenience, and potential costly failure of an on-sight, cryopreservation device.



   Company Address: 112 Westwood Place Brentwood 37027 TN
   Company Phone Number: 470-2300   Stock Exchange / Ticker: NASDAQ CYRX
   


Customers Net Income fell by CYRX's Customers Net Profit Margin fell to

-65.93 %

-0.01 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Cryoport Inc

Cryoport Inc Faces Challenges as Deficit Per Share Surges in Q4 2023

Cryoport Inc, a major player in the pharmaceutical preparations industry, recently released its financial results for the fourth quarter of the 2023 earnings season. The company reported a significant increase in its deficit per share, with a deficit of $-1.30 per share compared to $-0.22 in the same period the previous year. This represents a huge surge in deficit from the previous reporting period, where it was $-0.31 per share.
In terms of revenue, Cryoport Inc experienced a decrease of -5.133%, with revenue totaling $57.26 million compared to $60.36 million in the corresponding reporting period a year before. However, there was a slight sequential increase of 1.964% from the previous quarter.

Cryoport Inc

Cryoport Inc's latest fiscal period sees staggering losses surpassing previous year's figures at Major Pharma Preparations firm



Cryoport Inc, a leading provider of cold chain logistics solutions, has seen its stock gain 16.5% over the last five trading days, demonstrating some positive momentum. However, while this may seem promising, it is important to examine the recent financial results to understand the potential implications for the company's future.
1. Declining Revenue and Widening Losses:
In the most recent fiscal period, Cryoport Inc experienced a decline in revenue to $56.16 million, a decrease of 7.123% compared to the previous year. This decrease can be attributed to lower demand, which has resulted in fading revenue. Furthermore, the company's net loss for the period amounted to $-15.269 million, surpassing the $-7.316 million loss recorded in the previous year. The persisting losses pose significant challenges to Cryoport Inc's profitability and long-term sustainability.

Cryoport Inc

Cryoport Inc Reports Substantial Losses on Weak Sales Throughout Fiscal Second Quarter of 2023


Date: [Today's Date]
Cryoport Inc, a leading provider of critical temperature logistics solutions for the life sciences industry, has reported disappointing financial results for the second quarter of 2023. The company's loss per share increased to $-0.42 compared to $-0.23 a year ago, representing a significant surge from the previous financial reporting period's loss of $-0.16 per share.
Revenue for the April to June 30, 2023 span declined considerably by -11.117% to $57.02 million from $64.15 million in the corresponding financial reporting period a year ago. Sequentially, revenue deteriorated by -9.227% from $62.82 million. This decline is in stark contrast to the on-average Major Pharmaceutical Preparations sector, which recorded a 2.65% growth in revenue relative to Q2 2022 in the second quarter of 2023.

Cryoport Inc

Cryoport Inc Shows Promising Top-Line Growth in Q1 2023, but Sustainability Remains a Concern

Cryoport Inc seems to be on the rise based on their first quarter of 2023 results with a decrease in loss per share and an increase in earnings per share. However, upon closer inspection, there are indications that this positive development may not be sustainable in the long run.
Despite the reported decrease in loss per share, Cryoport Inc still reported a net deficit of $-7.574 million in the first quarter of 2023. While this is an improvement from the $-15.404 million deficit reported in the same period a year ago, the fact remains that the company is still not profitable.






 

Cryoport Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Cryoport Inc does not provide revenue guidance.

Earnings Outlook
Cryoport inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com